Skip to content

Study · Non-randomized trial · n = 14 · 2023

6 results

Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind study.

Akasaka H, Nakagami H, Sugimoto K, Yasunobe Y, Minami T, Fujimoto T, Yamamoto K, Hara C, Shiraki A, Nishida K, Asano K, Kanou M, Yamana K, Imai SI, Rakugi H

Geriatrics & gerontology international28 Nov 2022Cited by 26 (Europe PMC)

PMID36443648 (opens in a new tab)DOI10.1111/ggi.14513 (opens in a new tab)PepBankPUB-36443648
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In older men with diabetes and impaired physical performance, NMN was tolerable without severe adverse events.

    In plain wordsIn older men with diabetes and reduced physical performance, NMN was tolerated without severe adverse events.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Direction not reportedSevere adverse events
    Study

    n = 14

    Analysis
    Primary
    Outcome group
    Adverse events · Whole body
    Studied dose
    250 mg/day · oral · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    NMN was tolerable without any severe adverse events.
    2 context sentences
    Summary · context
    We carried out a 24-week placebo-controlled, double-blinded study of male patients with diabetes aged ≥65 years with reduced grip strength (<26 kg) or walking speed (<1.0 m/s).
    Summary · context
    The primary end-points were to determine the safety of NMN oral administration (250 mg/day), and changes in grip strength and walking speed.
  2. 02HumanNon-randomized trialEfficacy outcome

    In older men with diabetes, grip strength changes did not differ between NMN and placebo.

    In plain wordsIn older men with diabetes, grip strength changes did not differ between NMN and placebo.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeGrip strength change
    Study

    n = 14

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    250 mg/day · oral · 24 weeksAs given in this study (human).

    Measurements

    Grip strength change
    1.25 kg
    NMN group
    95% CI
    −2.31 to 4.81 kg
    NMN group
    Grip strength change
    −0.44 kg
    placebo group
    95% CI
    −4.15 to 3.26 kg
    placebo group

    Source sentences

    Summary
    The changes in grip strength and walking speed showed no difference between the two groups: 1.25 kg (95% confidence interval -2.31 to 4.81) and 0.033 m/s (-0.021 to 0.087) in the NMN group, and -0.44 kg (-4.15 to 3.26) and 0.014 m/s (-0.16 to -0.13) in the placebo group, respectively.
    2 context sentences
    Summary · context
    We carried out a 24-week placebo-controlled, double-blinded study of male patients with diabetes aged ≥65 years with reduced grip strength (<26 kg) or walking speed (<1.0 m/s).
    Summary · context
    The primary end-points were to determine the safety of NMN oral administration (250 mg/day), and changes in grip strength and walking speed.
  3. 03HumanNon-randomized trialEfficacy outcome

    In older men with diabetes, walking speed changes did not differ between NMN and placebo.

    In plain wordsIn older men with diabetes, walking speed changes did not differ between NMN and placebo.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeWalking speed change
    Study

    n = 14

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    250 mg/day · oral · 24 weeksAs given in this study (human).

    Measurements

    Walking speed change
    0.033 m/s
    NMN group
    95% CI
    −0.021 to 0.087 m/s
    NMN group
    Walking speed change
    0.014 m/s
    placebo group
    95% CI
    −0.16 to −0.13 m/s
    placebo group

    Source sentences

    Summary
    The changes in grip strength and walking speed showed no difference between the two groups: 1.25 kg (95% confidence interval -2.31 to 4.81) and 0.033 m/s (-0.021 to 0.087) in the NMN group, and -0.44 kg (-4.15 to 3.26) and 0.014 m/s (-0.16 to -0.13) in the placebo group, respectively.
    2 context sentences
    Summary · context
    We carried out a 24-week placebo-controlled, double-blinded study of male patients with diabetes aged ≥65 years with reduced grip strength (<26 kg) or walking speed (<1.0 m/s).
    Summary · context
    The primary end-points were to determine the safety of NMN oral administration (250 mg/day), and changes in grip strength and walking speed.
  4. 04HumanNon-randomized trialEfficacy outcome

    In older men with diabetes, exploratory indicators did not differ significantly between NMN and placebo.

    In plain wordsIn older men with diabetes, exploratory indicators did not differ significantly between NMN and placebo.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeExploratory indicators
    Study

    n = 14

    Comparator
    placebo
    Analysis
    Secondary
    Outcome group
    Overall treatment effect · Whole body
    Studied dose
    250 mg/day · oral · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in any exploratory indicators between the two groups.
    2 context sentences
    Summary · context
    We carried out a 24-week placebo-controlled, double-blinded study of male patients with diabetes aged ≥65 years with reduced grip strength (<26 kg) or walking speed (<1.0 m/s).
    Summary · context
    The primary end-points were to determine the safety of NMN oral administration (250 mg/day), and changes in grip strength and walking speed.
  5. 05HumanNon-randomized trialEfficacy outcome

    In older men with diabetes, central retinal thickness changes differed between NMN and placebo with P = 0.051.

    In plain wordsIn older men with diabetes, changes in retinal thickness differed between the NMN and placebo groups, with P = 0.051.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeCentral retinal thickness
    Study

    n = 14

    Comparator
    placebo
    Analysis
    Secondary
    Outcome group
    Vision and retina · Eye
    Studied dose
    250 mg/day · oral · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    However, improved prevalence of frailty in the NMN group (P = 0.066) and different changes in central retinal thickness between the two groups (P = 0.051) was observed.
    2 context sentences
    Summary · context
    We carried out a 24-week placebo-controlled, double-blinded study of male patients with diabetes aged ≥65 years with reduced grip strength (<26 kg) or walking speed (<1.0 m/s).
    Summary · context
    The primary end-points were to determine the safety of NMN oral administration (250 mg/day), and changes in grip strength and walking speed.
  6. 06HumanNon-randomized trialEfficacy outcome

    In older men with diabetes, frailty prevalence improved in the NMN group with P = 0.066.

    In plain wordsIn older men with diabetes, frailty prevalence improved in the NMN group, with P = 0.066.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeFrailty prevalence
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    250 mg/day · oral · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    However, improved prevalence of frailty in the NMN group (P = 0.066) and different changes in central retinal thickness between the two groups (P = 0.051) was observed.
    2 context sentences
    Summary · context
    We carried out a 24-week placebo-controlled, double-blinded study of male patients with diabetes aged ≥65 years with reduced grip strength (<26 kg) or walking speed (<1.0 m/s).
    Summary · context
    The primary end-points were to determine the safety of NMN oral administration (250 mg/day), and changes in grip strength and walking speed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.